-Livemint.com All our solutions in agriculture, besides management issues, are going to come from science and technology, says Deepak Pental, innovator of GM mustard Last week, the environment ministry’s regulator, the Genetic Engineering Appraisal Committee (GEAC), cleared the commercial release of genetically modified (GM) mustard, leaving it to the government to take a final call. If approved, it will be India’s first food crop developed using transgenic technology, 15 years after Bt...

-The Hindu PoS devices’ demand falls on remonetisation, user charges Cash transactions are beginning to trump almost every form of digital payment alternative with April clocking a decline in volumes as well as value of transactions conducted through cards, mobile banking and the Unified Payment Interface (UPI). The trend assumes significance six months after the Centre announced demonetisation of ?500 and ?1,000 notes on November 8. The near-completion of the remonetisation process and merchants...

-The Indian Express We have been numbed by a series of lies, myths and fictions about the project. India is at risk of becoming a surveillance state, with faint resistance from libertarians, intellectuals, political parties, the media, or the Supreme Court. Very soon, almost everyone will have an Aadhaar number, seeded in hundreds of databases. Most of these databases will be accessible to the government without invoking any special powers. Permanent surveillance...

-The Times of India NEW DELHI: Seeking to put to rest fears that the use of fake identification to obtain Aadhaar cards and the leak of data pose a security threat, Unique Identification Authority of India (UIDAI) CEO Ajay Bhushan Pandey has said that UID systems are secure and will deter terrorists and money launderers. The use of a fake Aadhaar ID will prove more hazardous to criminals as compared to...

-The Telegraph New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries. It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer. The pre-qualification process is a mechanism...